Dynavax rises in morning trading

Dynavax Technologies (DVAX +8.4%) posts solid gains in morning trading.

The company said Tuesday evening that immunogenicity and safety results from two Phase 3 Heplisav trials were published in Vaccine along with some commentary by two doctors.

Long story short, here's what was said: These two trials are further evidence that the adjuvant in Heplisav is "important" in hepatitis B immunization. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs